Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.

Mäkelä E, Löyttyniemi E, Salmenniemi U, Kauko O, Varila T, Kairisto V, Itälä-Remes M, Westermarck J.

Cancers (Basel). 2019 Nov 11;11(11). pii: E1774. doi: 10.3390/cancers11111774.

PMID:
31717978
2.

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.

O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G.

Oncogene. 2019 Sep 20. doi: 10.1038/s41388-019-1012-2. [Epub ahead of print]

PMID:
31541192
3.

Genistein Decreases APP/tau Phosphorylation and Ameliorates Aβ Overproduction Through Inhibiting CIP2A.

Shentu YP, Hu WT, Liang JW, Liuyang ZY, Wei H, Qun W, Wang XC, Wang JZ, Westermarck J, Liu R.

Curr Alzheimer Res. 2019;16(8):732-740. doi: 10.2174/1567205016666190830113420.

PMID:
31470788
4.

CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits.

Shentu YP, Hu WT, Zhang Q, Huo Y, Liang JW, Liuyang ZY, Zhou H, Wei H, Ke D, Wang XC, Wang JZ, Man HY, Westermarck J, Liu R.

Neurobiol Aging. 2019 Mar;75:198-208. doi: 10.1016/j.neurobiolaging.2018.11.023. Epub 2018 Dec 6.

PMID:
30594047
5.

Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.

Johannessen TC, Hasan-Olive MM, Zhu H, Denisova O, Grudic A, Latif MA, Saed H, Varughese JK, Røsland GV, Yang N, Sundstrøm T, Nordal A, Tronstad KJ, Wang J, Lund-Johansen M, Simonsen A, Janji B, Westermarck J, Bjerkvig R, Prestegarden L.

Int J Cancer. 2019 Apr 1;144(7):1735-1745. doi: 10.1002/ijc.31912. Epub 2018 Dec 11.

PMID:
30289977
6.

Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.

Westermarck J.

FEBS J. 2018 Nov;285(22):4139-4145. doi: 10.1111/febs.14617. Epub 2018 Aug 17. Review.

7.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.

PMID:
30021885
8.

Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J, Bronner ME.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7351-E7360. doi: 10.1073/pnas.1800039115. Epub 2018 Jul 18.

9.

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease.

Shentu YP, Huo Y, Feng XL, Gilbert J, Zhang Q, Liuyang ZY, Wang XL, Wang G, Zhou H, Wang XC, Wang JZ, Lu YM, Westermarck J, Man HY, Liu R.

Cell Rep. 2018 Jul 17;24(3):713-723. doi: 10.1016/j.celrep.2018.06.009.

10.

Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.

Birkman EM, Elzagheid A, Jokilehto T, Avoranta T, Korkeila E, Kulmala J, Syrjänen K, Westermarck J, Sundström J.

Cancer Med. 2018 Mar;7(3):698-706. doi: 10.1002/cam4.1361. Epub 2018 Feb 14.

11.

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.

Kauko O, Westermarck J.

Int J Biochem Cell Biol. 2018 Mar;96:157-164. doi: 10.1016/j.biocel.2018.01.005. Epub 2018 Jan 31. Review.

PMID:
29355757
12.

Phosphatases catching up with the level of knowledge: Finally druggable?

Westermarck J.

Int J Biochem Cell Biol. 2018 Mar;96:96-97. doi: 10.1016/j.biocel.2018.01.007. Epub 2018 Jan 11. No abstract available.

PMID:
29337252
13.

PWP1 Mediates Nutrient-Dependent Growth Control through Nucleolar Regulation of Ribosomal Gene Expression.

Liu Y, Mattila J, Ventelä S, Yadav L, Zhang W, Lamichane N, Sundström J, Kauko O, Grénman R, Varjosalo M, Westermarck J, Hietakangas V.

Dev Cell. 2017 Oct 23;43(2):240-252.e5. doi: 10.1016/j.devcel.2017.09.022.

14.

PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development.

Sents W, Meeusen B, Kalev P, Radaelli E, Sagaert X, Miermans E, Haesen D, Lambrecht C, Dewerchin M, Carmeliet P, Westermarck J, Sablina A, Janssens V.

Cancer Res. 2017 Dec 15;77(24):6825-6837. doi: 10.1158/0008-5472.CAN-16-2911. Epub 2017 Oct 18.

15.

Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.

Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W, Westermarck J.

EMBO Rep. 2017 Mar;18(3):437-450. doi: 10.15252/embr.201642788. Epub 2017 Feb 7.

16.

Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.

Prabhakar N, Zhang J, Desai D, Casals E, Gulin-Sarfraz T, Näreoja T, Westermarck J, Rosenholm JM.

Int J Nanomedicine. 2016 Dec 8;11:6591-6608. eCollection 2016.

17.

Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1.

Kaur A, Westermarck J.

Biochem Soc Trans. 2016 Dec 15;44(6):1683-1693. Review.

PMID:
27913678
18.

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.

Kaur A, Denisova OV, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, Raheem O, Haapasalo H, Eriksson J, Chalmers AJ, Laakkonen P, Westermarck J.

Cancer Res. 2016 Dec 1;76(23):7001-7011. Epub 2016 Sep 26.

19.

Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.

Kaukonen R, Mai A, Georgiadou M, Saari M, De Franceschi N, Betz T, Sihto H, Ventelä S, Elo L, Jokitalo E, Westermarck J, Kellokumpu-Lehtinen PL, Joensuu H, Grenman R, Ivaska J.

Nat Commun. 2016 Aug 4;7:12237. doi: 10.1038/ncomms12237.

20.

Optimized design and analysis of preclinical intervention studies in vivo.

Laajala TD, Jumppanen M, Huhtaniemi R, Fey V, Kaur A, Knuuttila M, Aho E, Oksala R, Westermarck J, Mäkelä S, Poutanen M, Aittokallio T.

Sci Rep. 2016 Aug 2;6:30723. doi: 10.1038/srep30723.

21.

CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection.

Côme C, Cvrljevic A, Khan MM, Treise I, Adler T, Aguilar-Pimentel JA, Au-Yeung B, Sittig E, Laajala TD, Chen Y, Oeder S, Calzada-Wack J, Horsch M, Aittokallio T, Busch DH, Ollert MW, Neff F, Beckers J, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Chen Z, Lahesmaa R, Westermarck J.

PLoS One. 2016 Apr 21;11(4):e0152996. doi: 10.1371/journal.pone.0152996. eCollection 2016.

22.

MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers.

Ventelä S, Mäkelä JA, Sears RC, Toppari J, Westermarck J.

Matters (Zur). 2016 Mar;2016. doi: 10.19185/matters.201602000040. Epub 2016 Mar 3.

23.

Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data.

Pokharel YR, Saarela J, Szwajda A, Rupp C, Rokka A, Lal Kumar Karna S, Teittinen K, Corthals G, Kallioniemi O, Wennerberg K, Aittokallio T, Westermarck J.

Mol Cell Proteomics. 2015 Dec;14(12):3274-83. doi: 10.1074/mcp.M115.050773. Epub 2015 Oct 23.

24.

Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma.

Routila J, Bilgen T, Saramäki O, Grénman R, Visakorpi T, Westermarck J, Ventelä S.

J Oral Pathol Med. 2016 May;45(5):329-37. doi: 10.1111/jop.12372. Epub 2015 Oct 5.

PMID:
26436875
25.

Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.

Routila J, Mäkelä JA, Luukkaa H, Leivo I, Irjala H, Westermarck J, Mäkitie A, Ventelä S.

Genes Chromosomes Cancer. 2016 Jan;55(1):69-81. doi: 10.1002/gcc.22312. Epub 2015 Sep 23.

PMID:
26395031
26.

Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.

Kaur A, Elzagheid A, Birkman EM, Avoranta T, Kytölä V, Korkeila E, Syrjänen K, Westermarck J, Sundström J.

Cancer Med. 2015 Dec;4(12):1798-808. doi: 10.1002/cam4.541. Epub 2015 Sep 17.

27.

Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling.

Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J, Imanishi SY.

Sci Rep. 2015 Aug 17;5:13099. doi: 10.1038/srep13099.

28.

Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation.

Myant K, Qiao X, Halonen T, Come C, Laine A, Janghorban M, Partanen JI, Cassidy J, Ogg EL, Cammareri P, Laiterä T, Okkeri J, Klefström J, Sears RC, Sansom OJ, Westermarck J.

Cell Rep. 2015 Aug 11;12(6):1019-31. doi: 10.1016/j.celrep.2015.07.003. Epub 2015 Jul 30.

29.

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V, Pimanda JE, Maitland NJ, Westermarck J, Visakorpi T.

Oncotarget. 2015 Aug 14;6(23):19661-70.

30.

KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.

Pekkonen P, Järviluoma A, Zinovkina N, Cvrljevic A, Prakash S, Westermarck J, Evan GI, Cesarman E, Verschuren EW, Ojala PM.

Cell Cycle. 2014;13(23):3670-84. doi: 10.4161/15384101.2014.964118.

31.

CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance.

Ventelä S, Sittig E, Mannermaa L, Mäkelä JA, Kulmala J, Löyttyniemi E, Strauss L, Cárpen O, Toppari J, Grénman R, Westermarck J.

Oncotarget. 2015 Jan 1;6(1):144-58.

32.

Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.

Laine A, Westermarck J.

Clin Cancer Res. 2014 Jul 15;20(14):3644-50. doi: 10.1158/1078-0432.CCR-13-1942. Epub 2014 May 1. Review.

33.

ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays.

Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D.

PLoS One. 2014 Mar 19;9(3):e92444. doi: 10.1371/journal.pone.0092444. eCollection 2014.

34.

Mesoporous silica nanoparticles with redox-responsive surface linkers for charge-reversible loading and release of short oligonucleotides.

Zhang J, Niemelä M, Westermarck J, Rosenholm JM.

Dalton Trans. 2014 Mar 14;43(10):4115-26. doi: 10.1039/c3dt53071j.

PMID:
24457531
35.

Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.

Khanna A, Pimanda JE, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6548-53. doi: 10.1158/0008-5472.CAN-13-1994. Epub 2013 Nov 7. Review.

36.

Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefström J, Aittokallio T, Weiss C, Ristimäki A, Visakorpi T, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6757-69. doi: 10.1158/0008-5472.CAN-13-1002. Epub 2013 Sep 26.

37.

Identification of protein interactions involved in cellular signaling.

Westermarck J, Ivaska J, Corthals GL.

Mol Cell Proteomics. 2013 Jul;12(7):1752-63. doi: 10.1074/mcp.R113.027771. Epub 2013 Mar 12. Review.

38.

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J.

Cancer Discov. 2013 Feb;3(2):182-97. doi: 10.1158/2159-8290.CD-12-0292. Epub 2013 Jan 10.

39.

Nucleolar AATF regulates c-Jun-mediated apoptosis.

Ferraris SE, Isoniemi K, Torvaldson E, Anckar J, Westermarck J, Eriksson JE.

Mol Biol Cell. 2012 Nov;23(21):4323-32. doi: 10.1091/mbc.E12-05-0419. Epub 2012 Aug 29.

40.

CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice.

Ventelä S, Côme C, Mäkelä JA, Hobbs RM, Mannermaa L, Kallajoki M, Chan EK, Pandolfi PP, Toppari J, Westermarck J.

PLoS One. 2012;7(3):e33209. doi: 10.1371/journal.pone.0033209. Epub 2012 Mar 26.

41.

Identification and regulation of a stage-specific stem cell niche enriched by Nanog-positive spermatogonial stem cells in the mouse testis.

Ventelä S, Mäkelä JA, Kulmala J, Westermarck J, Toppari J.

Stem Cells. 2012 May;30(5):1008-20. doi: 10.1002/stem.1077.

42.

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.

Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J.

Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16.

PMID:
22249265
43.

Prognostic role of CIP2A expression in serous ovarian cancer.

Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A.

Br J Cancer. 2011 Sep 27;105(7):989-95. doi: 10.1038/bjc.2011.346. Epub 2011 Sep 6.

44.

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.

Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bøttzauw T, Nielsen CF, Willumsen BM, Hautaniemi S, Lahesmaa R, Westermarck J, Jäättelä M, Kallunki T.

Oncogene. 2012 Jan 19;31(3):390-401. doi: 10.1038/onc.2011.230. Epub 2011 Jun 27.

PMID:
21706057
45.

ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.

Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J.

PLoS One. 2011 Mar 22;6(3):e17979. doi: 10.1371/journal.pone.0017979.

46.

Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme.

Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomäki V, Valo E, Núñez-Fontarnau J, Rantanen V, Karinen S, Nousiainen K, Lahesmaa-Korpinen AM, Miettinen M, Saarinen L, Kohonen P, Wu J, Westermarck J, Hautaniemi S.

Genome Med. 2010 Sep 7;2(9):65. doi: 10.1186/gm186.

47.

Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun.

Westermarck J.

Methods Mol Biol. 2010;647:31-6. doi: 10.1007/978-1-60761-738-9_2. Review.

PMID:
20694659
48.

CIP2A increases self-renewal and is linked to Myc in neural progenitor cells.

Kerosuo L, Fox H, Perälä N, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H, Wartiovaara K.

Differentiation. 2010 Jul;80(1):68-77. doi: 10.1016/j.diff.2010.04.003. Epub 2010 May 5.

PMID:
20447748
49.

Hypoxia-activated Smad3-specific dephosphorylation by PP2A.

Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, Kähäri VM, Jaakkola PM.

J Biol Chem. 2010 Feb 5;285(6):3740-9. doi: 10.1074/jbc.M109.042978. Epub 2009 Dec 1.

50.

CIP2A is associated with human breast cancer aggressivity.

Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J.

Clin Cancer Res. 2009 Aug 15;15(16):5092-100. doi: 10.1158/1078-0432.CCR-08-3283. Epub 2009 Aug 11.

Supplemental Content

Loading ...
Support Center